Key Points Hims & Hers Health is entering the Canadian market.The company will offer a generic version of semaglutide in the ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

HIMS benefits from strong online revenue, subscriber growth, and global expansion moves to fuel its health platform momentum. However, challenges may hurt performance.

HIMS rebounds on GLP-1 growth and rising earnings estimates, while DXC slumps amid falling sales and eroding investor ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.